한빛사 논문
Min Joo Choia,1, Ju-Yeon Choib,1, Hakjun Hyunc, Eliel Nhamc, Hye Seongc, Jin Gu Yoonc, Ji Yun Nohc,d, Hee Jin Cheongc,d, Woo Joo Kimc,d, Su-Hwan Kimb, Hyeonji Jeongb, Min-Seong Kimb, Byoungguk Kimb,*, Joon Young Songc,d,*
aDepartment of Internal Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Republic of Korea
bDivision of Vaccine Clinical Research, Center for Vaccine Research, National Institute of Infectious Diseases, Korea National Institute of Health, Cheongju, Republic of Korea
cDivision of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea
dVaccine Innovation Center-KU Medicine (VIC-K), Seoul, Republic of Korea
*Corresponding author.
Abstract
Dear editors
Since the first emergence in November 2021, the SARS-CoV-2 B.1.1.529 (Omicron) variant had become the dominant strain worldwide, leading to a large increase in the number of COVID-19 cases. After then, the antecedent Omicron BA.1 strain has been replaced by Omicron BA.4 and BA.5 subvariants, which are highly transmissible, and more immune-evading from vaccines (1). In a previous study by Yadav et al., reduced neutralization was observed against Omicron variant after 2-dose primary series vaccination (2). Booster vaccination is expected to enhance the cross-neutralization activity against Omicron subvariants.
논문정보
관련 링크
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기